Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2

Molecular Immunology

Volumn 53, Issue 1-2, 2013, Pages 126-131

  Lampen, Margit H ^a   Hassan, Chopie ^a   Sluijter, Marjolein ^a   Geluk, Annemieke ^a   Dijkman, Karin ^a   Tjon, Jennifer M ^a   de Ru, Arnoud H ^a   van der Burg, Sjoerd H ^a   van Veelen, Peter A ^a   van Hall, Thorbald ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antigen processing; Class Ib; HLA A2; HLA E; MHC binding motif; Non classical HLA

Indexed keywords

HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; HLA E ANTIGEN;

AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; HYDROPHOBICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MOTIF;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A2 ANTIGEN; HUMANS; K562 CELLS; MOLECULAR SEQUENCE DATA; PROTEIN SORTING SIGNALS; TRANSFECTION;

EID: 84864936907     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2012.07.009     Document Type: Article

References (33)

1. Braud V., Jones E.Y., McMichael A. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. European Journal of Immunology 1997, 27:1164-1169.
2. Braud V.M., Allan D.S., O'Callaghan C.A., Soderstrom K., D'Andrea A., Ogg G.S., Lazetic S., Young N.T., Bell J.I., Phillips J.H., Lanier L.L., McMichael A.J. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998, 391:795-799.
3. Colaert N., Helsens K., Martens L., Vandekerckhove J., Gevaert K. Improved visualization of protein consensus sequences by IceLogo. Nature Methods 2009, 6:786-787.
4. Coupel S., Moreau A., Hamidou M., Horejsi V., Soulillou J.P., Charreau B. Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood 2007, 109:2806-2814.
5. Derre L., Corvaisier M., Charreau B., Moreau A., Godefroy E., Moreau-Aubry A., Jotereau F., Gervois N. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. Journal of Immunology 2006, 177:3100-3107.
6. Durgeau A., El Hage F., Vergnon I., Validire P., de Montpreville V., Besse B., Soria J.C., van Hall T., Mami-Chouaib F. Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL. Journal of Immunology 2011, 187:5532-5539.
7. Gil-Torregrosa B.C., Castano A.R., Lopez D., Del Val M. Generation of MHC class I peptide antigens by protein processing in the secretory route by furin. Traffic 2000, 1:641-651.
8. Gooden M., Lampen M., Jordanova E.S., Leffers N., Trimbos J.B., van der Burg S.H., Nijman H., van Hall T. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8 T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:10656-10661.
9. Joosten S.A., van Meijgaarden K.E., van Weeren P.C., Kazi F., Geluk A., Savage N.D., Drijfhout J.W., Flower D.R., Hanekom W.A., Klein M.R., Ottenhoff T.H. Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. PLoS Pathogens 2010, 6:e1000782.
10. Kessler J.H., Mommaas B., Mutis T., Huijbers I., Vissers D., Benckhuijsen W.E., Schreuder G.M., Offringa R., Goulmy E., Melief C.J., van der Burg S.H., Drijfhout J.W. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. Human Immunology 2003, 64:245-255.
11. Kurepa Z., Hasemann C.A., Forman J. Qa-1b binds conserved class I leader peptides derived from several mammalian species. Journal of Experimental Medicine 1998, 188:973-978.
12. + T cell responses against TAP-inhibited cells are readily detected in the human population. Journal of Immunology 2010, 185:6508-6517.
13. Martoglio B., Dobberstein B. Signal sequences: more than just greasy peptides. Trends in Cell Biology 1998, 8:410-415.
14. Mazzarino P., Pietra G., Vacca P., Falco M., Colau D., Coulie P., Moretta L., Mingari M.C. Identification of effector-memory CMV-specific T lymphocytes that kill CMV-infected target cells in an HLA-E-restricted fashion. European Journal of Immunology 2005, 35:3240-3247.
15. Michaelsson J., Teixeira de Matos C., Achour A., Lanier L.L., Karre K., Soderstrom K. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. Journal of Experimental Medicine 2002, 196:1403-1414.
16. Miller J.D., Weber D.A., Ibegbu C., Pohl J., Altman J.D., Jensen P.E. Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94/NKG2. Journal of Immunology 2003, 171:1369-1375.
17. Nattermann J., Nischalke H.D., Hofmeister V., Ahlenstiel G., Zimmermann H., Leifeld L., Weiss E.H., Sauerbruch T., Spengler U. The HLA-A2 restricted T cell epitope HCV core 35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells. American Journal of Pathology 2005, 166:443-453.
18. O'Callaghan C.A., Tormo J., Willcox B.E., Braud V.M., Jakobsen B.K., Stuart D.I., McMichael A.J., Bell J.I., Jones E.Y. Structural features impose tight peptide binding specificity in the nonclassical MHC molecule HLA-E. Molecular Cell 1998, 1:531-541.
19. + T cell surveillance of antigen-processing defects. The Journal of Experimental Medicine 2010, 207:207-221.
20. Oliveira C.C., Querido B., Sluijter M., Derbinski J., van der Burg S.H., van Hall T. Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires. European Journal of Immunology 2011, 41:3114-3124.
21. Rodgers J.R., Cook R.G. MHC class Ib molecules bridge innate and acquired immunity. Nature Reviews Immunology 2005, 5:459-471.
22. Sensi M., Pietra G., Molla A., Nicolini G., Vegetti C., Bersani I., Millo E., Weiss E., Moretta L., Mingari M.C., Anichini A. Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5. International Immunology 2009, 21:257-268.
23. Sette A., Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999, 50:201-212.
24. Skowera A., Ellis R.J., Varela-Calvino R., Arif S., Huang G.C., Van-Krinks C., Zaremba A., Rackham C., Allen J.S., Tree T.I., Zhao M., Dayan C.M., Sewell A.K., Unger W.W., Drijfhout J.W., Ossendorp F., Roep B.O., Peakman M. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. Journal of Clinical Investigation 2008, 118:3390-3402.
25. Snyder H.L., Bacik I., Yewdell J.W., Behrens T.W., Bennink J.R. Promiscuous liberation of MHC-class I-binding peptides from the C termini of membrane and soluble proteins in the secretory pathway. European Journal of Immunology 1998, 28:1339-1346.
26. Stevens J., Joly E., Trowsdale J., Butcher G.W. Peptide binding characteristics of the non-classical class Ib MHC molecule HLA-E assessed by a recombinant random peptide approach. BMC Immunology 2001, 2:5.
27. Strong R.K., Holmes M.A., Li P., Braun L., Lee N., Geraghty D.E. HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. Journal of Biological Chemistry 2003, 278:5082-5090.
28. Tey S.K., Khanna R. Autophagy mediates transporter associated with antigen pathway processing-independent presentation of viral epitopes through MHC class I. Blood 2012, 120:994-1004.
29. van Hall T., Wolpert E.Z., van Veelen P., Laban S., van der Veer M., Roseboom M., Bres S., Grufman P., de Ru A., Meiring H., de Jong A., Franken K., Teixeira A., Valentijn R., Drijfhout J.W., Koning F., Camps M., Ossendorp F., Karre K., Ljunggren H.G., Melief C.J., Offringa R. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nature Medicine 2006, 12:417-424.
30. van Hall T., Oliveira C.C., Joosten S.A., Ottenhoff T.H. The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress. Microbes and Infection 2010, 12:910-918.
31. Verweij M.C., Ressing M.E., Knetsch W., Quinten E., Halenius A., van Bel N., Hengel H., Drijfhout J.W., van Hall T., Wiertz E.J. Inhibition of mouse TAP by immune evasion molecules encoded by non-murine herpesviruses. Molecular Immunology 2011, 48:835-845.
32. Vyas J.M., Van der Veen A.G., Ploegh H.L. The known unknowns of antigen processing and presentation. Nature Reviews. Immunology 2008, 8:607-618.
33. Weinzierl A.O., Rudolf D., Hillen N., Tenzer S., van Endert P., Schild H., Rammensee H.G., Stevanovic S. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. European Journal of Immunology 2008, 38:1503-1510.